Nature Reviews Neurology

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	484
Lymphatic propagation of α-synuclein	474
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	405
Brain stimulation aids walking after spinal injury	354
Reply to ‘Perils and pitfalls of near-death experience research’	338
ANA2025 marks important milestones for the ANA and NINDS	337
Genetic insights from Parkinson disease in African and African admixed populations	296
Neural cell state shifts and fate loss in ageing and age-related diseases	275
Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system	259
Global synergistic actions to improve brain health for human development	236
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	218
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	206
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	195
Disease-specific modifications of tau protein	188
Continuous levodopa production by an artificial enzyme	185
TREM2 mediates phagocytosis in glioblastoma	183
SEQUINS — a new initiative to address disparities in neurology	175
Nir Giladi (1955–2024)	173
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	172
Spinal muscular atrophy treatment in utero	172
Gut macrophages involved in Parkinson disease pathogenesis	164
Mitochondrial DNA instability in Huntington disease	160
Imperatives and co-benefits of research into climate change and neurological disease	150
The role of the gut microbiota in multiple sclerosis	149
The Digitized Memory Clinic	144

The impact of rare genetic variants on Alzheimer disease	120
Psychosis-causing lesions mapped to a hippocampal circuit	120
Ultrasound lets gene therapy into the brain	117
Brain volume is associated with cognition in MS	116
Amyloid plaques: hotspots for microglial turnover	116
Challenges of combining multimodal data in assessment of people with traumatic brain injury	114
MRI-based deep learning for TLE diagnosis	106
The challenges of anti-tau therapeutics in Alzheimer disease	104
Motor neuron disease in Africa: a critical appraisal of the literature	102
The World Brain Health Forum: breaking silos for co-ordinated action	98
Gene therapy for seizures in focal cortical dysplasia	97
Diversity, equity and inclusion in neurology	94
First trials test targeting of α-synuclein for Parkinson disease	93
Implications of AD plasma and PET biomarker discordance	88
Parkinson disease pathology can originate in the kidney	87
Precision neuroimmunology in multiple sclerosis — the horizon is near	87
Author Correction: Viral pathogens increase risk of neurodegenerative disease	86
Neuroinflammation predicts cognitive decline in FTD	85
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	84
Management of freezing of gait — mechanism-based practical recommendations	81
Neurological care for LGBT+ people	77
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	76
Low-field MRI for equitable epilepsy diagnosis in resource-limited settings	74
α-Synuclein pathology as a target in neurodegenerative diseases	71
Chromosome 21 gene DSCAM drives Down syndrome phenotypes	71
Neurosteroids alleviate seizures in rats	70
Glymphatic dysfunction in PD clinical progression	68
Ultrasound ablation treatment for PD	65
Addressing disparities in neurology by building the workforce in LMICs	65
A new biological classification for Parkinson disease	65
Thalamic inflammation — a therapeutic target for brain injury?	63
Food is brain medicine — relevance and translation to neurology	61
Spinal cord stimulation for the treatment of chronic pain	60
Skull bone marrow changes in multiple sclerosis	60
Newborn screening for spinal muscular atrophy: time is motor neuron	59
Coeliac disease as a model for understanding multiple sclerosis	57
Brain-first and body-first subtypes of Lewy body disease	56
New IDEAS about amyloid, race and dementia disparities	54
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	54
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	54
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	52
Is Alzheimer disease a disease?	51
The global and regional burden of diabetic peripheral neuropathy	51
Synaptic degeneration in Alzheimer disease	51
Neurofilament light chain induces neuroinflammation	48
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	48
Neurology in 2025 — reflections from Africa	48
Hypothyroidism is associated with dementia risk	48
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	48
X-chromosome variants and PD in Latin America	48

Lorenzo’s House: shining a light on young-onset dementia	47
Oligomeric tau could spread through synapses in AD	46
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	41
The inter-relationship between delirium and dementia: the importance of delirium prevention	40
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	40
Global epidemiology of migraine and its implications for public health and health policy	40
Risk locus for paediatric astrocytoma identified	39
α-Synuclein seeds in amyotrophic lateral sclerosis	37
Moving towards meaningful patient and public engagement	37
Prognostic plasma biomarkers for spinal cord injury	35
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	35
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	34
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	34
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	34
Promoting collaboration at the brain–heart interface	34
Reply to ‘Recalled experiences of death: need for empirical research without prejudice’	33
CAR T cells offer hope in glioblastoma	33
Neurology in 2025 — reflections from the USA	32
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	32
Christina Kim: functional and biochemical mapping of neural circuits	30
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	30
Huntington disease-like 2: insight into neurodegeneration from an African disease	30
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	29
Dual function of biomolecular condensates	29
New developments in guidelines for brain death/death by neurological criteria	28
Psychological interventions for migraine	28
Understanding the long-term neurological effects of SARS-CoV-2 infection	27
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	27
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
ALS pathogenesis linked to actin barrier collapse	25
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	25
Author Correction: The complex aetiology of cerebral palsy	25
Urogenital dysfunction in neurological diseases	23
Pharmacological rehabilitation for stroke	22
Serum NfL as an MS biomarker	22
Immune gateways bypass blood–brain barrier for drug delivery in stroke	22
AI aces diagnosis of chronic ataxias	22
AI and protein structure and function in neurological disease: relevance to disease management	22
BCAS1+ oligodendrocytes aid remyelination in MS	20
The murky waters of sex differences in post-stroke cognitive impairment	20
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	20
Molecular biomarkers for vascular cognitive impairment and dementia	19
Pathogenetic mechanisms and treatment targets in cerebral malaria	19
Clocking the age of Parkinson disease onset	18
Addressing disparities in the global epidemiology of stroke	18
Effects of diet on MS onset and course	18
The potential of low-field MRI for global dementia care	18
Altered muscle cholesterol transport in ALS	17
Nanoprobe for blood–brain barrier changes	16
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions	16
Predictive tools in psychosis: what is ‘good enough’?	16
Alzheimer disease seen through the lens of sex and gender	15
Advancing multiple sclerosis management in older adults	15
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	14
Markers help to predict dementia with Lewy bodies	14
Sex and gender in neurodevelopmental conditions	14
Mechanistic insights into the interaction between epilepsy and sleep	14
From adaptive deep brain stimulation to adaptive circuit targeting	14
Seizure-associated changes in the Golgi apparatus	13
Multidimensional MRI detects astrogliosis	13
Limitations of neurocentric models for near-death experiences	13
Evidence-based clinical care and policy making for schizophrenia	13
Shared glial pathology in HD and schizophrenia	13
Author Correction: Why functional neurological disorder is not feigning or malingering	13
Alzheimer disease in Down syndrome linked to APOE	13
Walking the Talk for Dementia — an experience to break down barriers	13
Timing of hormone replacement therapy could influence Alzheimer disease risk	12
Advances in the therapeutic algorithm for myasthenia gravis	12
Parkinson disease pathology in inflammatory bowel disease	12
Immune mechanisms and shared immune targets in neurodegenerative diseases	12
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	12
Moving artificial intelligence from research to real-world clinical use in neurology	11
Inclusion in neurological research: empowering people living with neurological diseases	11
Artificial intelligence in epilepsy — applications and pathways to the clinic	11
Multisite chronic pain: a risk factor for dementia	11
Psychiatric sequelae of traumatic brain injury — future directions in research	10
Identification of neurons involved in schizophrenia	10
Adaptive deep brain stimulation in Parkinson disease: clinical implementation and outlook	10
MS drug beneficial in an underrepresented group	10

A global view of the genetic basis of Alzheimer disease	10
T cell–microbiome communication influences disease in MS model	10
Peripheral B cells altered in Parkinson disease	9
PD pathology spread linked to mtDNA damage	9
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets	9
Recycling brain scans with AI	9
Glymphatic dysfunction detected in bvFTD	9
Multifaceted roles of APOE in Alzheimer disease	8
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	8
Sensory feedback in upper limb prosthetics: advances and challenges	8
Characteristics and mechanisms of cognitive impairment in Parkinson disease	8
Astrocytes in the initiation and progression of epilepsy	8
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	8
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	7
Calcium dysregulation could underlie lysosomal impairment in AD	7
Stem cells show promise in Parkinson disease	7
Addressing disparities in neurology by enhancing inclusive practice	7
Implications of immunometabolism for smouldering MS pathology and therapy	7
Oestrogen receptor variants linked to AD traits	7
Dementia risk scores in diverse populations	7
Translating lifestyle interventions for optimal brain health in Africa	6
BTK inhibitor falters in multiple sclerosis trials	6
From precision diagnosis to precision treatment in epilepsy	6
Addressing multiple sclerosis disparities in Latin American and other populations	6
Functional brain networks in the evaluation of patients with neurodegenerative disorders	6
Bidirectional brain–heart interactions in health and disease	6
Qiang Liu: addressing unmet clinical needs through neuroimmune mechanisms	6
Oligodendrocyte progenitor cell transplant for MS	5
Sleep and circadian disturbances in children with neurodevelopmental disorders	5
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	5
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	5
Novel plasma markers for Parkinson disease	5
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	5
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	5
EBV-specific T cells in multiple sclerosis	5
New CRISPR-based strategies for Alzheimer disease	5
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	5
Lewy bodies do not correlate with neuronal degeneration in DLB	5
Engineered TREM2 antibody clears Aβ in mice	5
Finger-prick blood test for Alzheimer disease	4
Addressing disparities in neurology by identifying gaps in hospital care	4
Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice	4
Insights into the toxic effects of mutant huntingtin	4
Disentangling clinical and biological trajectories of neurodegenerative diseases	4
Glioblastoma tackled with oncolytic virus	4
Epidemiology and characteristics of multiple sclerosis in Latin America	4
A biomarker for mild cognitive impairment	4
GluA2 modulator targets excitotoxicity in MS	4
Microglial senescence is a potential therapeutic target for Alzheimer disease	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
‘On-demand’ gene therapy for epilepsy	4
Exome sequencing identifies risk variants for AD	4
Bo Peng: microglia replacement therapy from bench to bedside	4
Skin α-synuclein differentiates synucleinopathies	4
APOE ε4 is linked to relapse-associated disability accrual in MS	4
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder	4
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	4
Bruton tyrosine kinase inhibitors for multiple sclerosis	4
New local therapy strategies for brain tumours	4
WNT receptor variant linked to synaptic degeneration	4
Nutritional and metabolic factors in amyotrophic lateral sclerosis	3
The changing landscape of primary autoimmune neuropathies	3
Lecanemab trial in AD brings hope but requires greater clarity	3
Veronique Miron: targeting neuroimmunology to protect myelin	3
Why functional neurological disorder is not feigning or malingering	3
Glioblastomas divert glucose to promote growth	3
Advances in PET imaging of protein aggregates associated with neurodegenerative disease	3
Ataxia Global Initiative recommend MRI end-points for clinical trials in ataxias	3
The influence of MOGAD on diagnosis of multiple sclerosis using MRI	3
Autoimmune encephalitis-associated epilepsy	3
Environmental–genetic interactions in ageing and dementia across Latin America	3
Microglial phagocytosis in Alzheimer disease	3
Spreading depolarization as a therapeutic target in migraine	3
Progress and challenges in sporadic late-onset cerebellar ataxias	3
Glyphosate and neurotoxicity — a call for scientific renewal	3
Parkinson disease therapy: current strategies and future research priorities	3
Phagocytes linked to cognitive dysfunction in neuro-HIV	3
A tale of race and B cells in multiple sclerosis	3
Domestic violence and chronic traumatic encephalopathy — an under-recognized link	3
Epigenetic clocks and DNA methylation biomarkers of brain health and disease	3
Anne-Katrin Pröbstel: B cells, antibodies and microbiota in autoimmune disease	3
White matter hyperintensities — location matters	3
Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives	3
FDA-approved drug promotes remyelination	2
Author Correction: Pathogenetic mechanisms and treatment targets in cerebral malaria	2
Inverse association between age and inflammatory disease activity in multiple sclerosis	2
Clinical implications of brain asymmetries	2
Trans-synaptic tau propagation in progressive supranuclear palsy	2
Exploring factors that confer cognitive resilience	2
Author Correction: A neuroscientific model of near-death experiences	2
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	2
A role for lithium in Alzheimer disease	2
Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’	2
Targeting toxic HTT1a could be the key to treating Huntington disease	2
Clinical outcomes evolve years after traumatic brain injury	2